MedTrace Logo

Efficacy of Repaglinide in Subjects With Type 2 Diabetes

NCT01698931 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2017-02-20

No results posted yet for this study

Summary

This trial is conducted in Europe. The aim of this trial is to compare the efficacy of repaglinide to glyburide and placebo on hepatic glucose metabolism in subjects with type 2 diabetes.

Conditions

Interventions

DRUG

repaglinide

1 mg before each main meal on three separate dosing visits separated by a wash-out period

DRUG

glyburide

5 mg before breakfast and before supper on three separate dosing visits separated by a wash-out period

DRUG

placebo

Before each main meal on three separate dosing visits separated by a wash-out period

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-04-26
Primary Completion
2003-03-06
Completion
2003-03-06

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01698931 on ClinicalTrials.gov